Home » Stocks » FHTX

Foghorn Therapeutics, Inc. (FHTX)

Stock Price: $10.90 USD -0.60 (-5.22%)
Updated Apr 19, 2021 11:04 AM EDT - Market open
Market Cap 120.41M
Revenue (ttm) 430,000
Net Income (ttm) -68.80M
Shares Out 11.05M
EPS (ttm) -6.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $10.90
Previous Close $11.50
Change ($) -0.60
Change (%) -5.22%
Day's Open 11.60
Day's Range 10.85 - 11.60
Day's Volume 10,853
52-Week Range 10.85 - 28.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, KLDO, MCRB, MRNA ...
1 month ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

1 month ago - GlobeNewsWire

US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeSciences plans...

Other stocks mentioned: GHLD, MCFE, MSP, NARI, SLQT
5 months ago - Seeking Alpha

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

5 months ago - GlobeNewsWire

Foghorn Therapeutics Files Terms For $120 Million IPO

5 months ago - Seeking Alpha

Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to raise up ...

6 months ago - Market Watch

About FHTX

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. Breakdowns in the chromatin regulatory system are associated wit... [Read more...]

Industry
Biotechnology
IPO Date
Oct 23, 2020
CEO
Adrian Gottschalk
Employees
95
Stock Exchange
NASDAQ
Ticker Symbol
FHTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is 25.00, which is an increase of 129.36% from the latest price.

Price Target
$25.00
(129.36% upside)
Analyst Consensus: Buy